↓ Skip to main content

The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial

Overview of attention for article published in BMC Psychiatry, September 2016
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Readers on

mendeley
244 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial
Published in
BMC Psychiatry, September 2016
DOI 10.1186/s12888-016-1031-2
Pubmed ID
Authors

Daisuke Nishi, Kuan-Pin Su, Kentaro Usuda, Yi-Ju Jill Chiang, Tai-Wei Guu, Kei Hamazaki, Naoki Nakaya, Toshimasa Sone, Yo Sano, Yoshiyuki Tachibana, Hiroe Ito, Keiich Isaka, Kenji Hashimoto, Tomohito Hamazaki, Yutaka J Matsuoka

Abstract

Maternal depression can be harmful to both mothers and their children. Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been investigated as an alternative intervention for pregnant women with depressive symptoms because of the supporting evidence from clinical trials in major depression, the safety advantage, and its anti-inflammatory and neuroplasticity effects. This study examines the efficacy of omega-3 PUFA supplementation for pregnant women with depressive symptoms in Taiwan and Japan, to provide evidence available for Asia. The rationale and protocol of this trial are reported here. The Synchronized Trial on Expectant Mothers with Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) is a multicenter, double-blind, parallel group, randomized controlled trial. Participants will be randomized to either the omega-3 PUFAs arm (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily) or placebo arm. Primary outcome is total score on the Hamilton Rating Scale for Depression (HAMD) at 12 weeks after the start of the intervention. We will randomize 56 participants to have 90 % power to detect a 4.7-point difference in mean HAMD scores with omega-3 PUFAs compared with placebo. Because seafood consumption varies across countries and this may have a major effect on the efficacy of omega-3 PUFA supplementation, 56 participants will be recruited at each site in Taiwan and Japan, for a total number of 112 participants. Secondary outcomes include depressive symptoms at 1 month after childbirth, diagnosis of major depressive disorder, changes in omega-3 PUFAs concentrations and levels of biomarkers at baseline and at 12 weeks' follow-up, and standard obstetric outcomes. Data analyses will be by intention to treat. The trial was started in June 2014 and is scheduled to end in February 2018. The trial is expected to provide evidence that can contribute to promoting mental health among mothers and children in Asian populations. Clinicaltrials.gov: NCT02166424 . Registered 15 June 2014; University Hospital Medical Information Network (UMIN) Center: UMIN000017979. Registered 20 May 2015.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 244 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Unknown 243 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 36 15%
Student > Master 35 14%
Researcher 20 8%
Student > Ph. D. Student 18 7%
Student > Doctoral Student 15 6%
Other 38 16%
Unknown 82 34%
Readers by discipline Count As %
Medicine and Dentistry 45 18%
Psychology 43 18%
Nursing and Health Professions 23 9%
Social Sciences 11 5%
Biochemistry, Genetics and Molecular Biology 6 2%
Other 24 10%
Unknown 92 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2017.
All research outputs
#19,292,491
of 23,881,329 outputs
Outputs from BMC Psychiatry
#4,109
of 4,939 outputs
Outputs of similar age
#248,200
of 324,028 outputs
Outputs of similar age from BMC Psychiatry
#67
of 76 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,939 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.9. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,028 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.